Has the NIB share price now peaked at $8?

Can the NIB train keep chugging higher or is it time to disembark?

| More on:
a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price has been a very strong performer over the last six months.

Since this time in November, the private health insurer's shares have raced 19% higher.

As a comparison, over the same period, the benchmark ASX 200 index has gained just 1.5%.

This leaves the NIB share price trading at $8.00, which is just 20 cents short of its 52-week high.

Why has the NIB share price outperformed?

Investors have been buying NIB's shares due to its improved outlook and recent update.

That update revealed that the company has raised its guidance for net policyholder growth for Australian residents in FY 2023 to 4% to 5% from 3% to 4%.

Management also revealed that ancillary claims are returning to normal, hospital claims are showing a modest uplift but remain subdued, and its net margins remain strong with a gradual return to its 6% to 7% target expected over the longer term.

Can its shares keep rising or have they peaked?

As things stand, the broker community appears to believe that the NIB share price may have peaked for the time being.

For example, Citi and Morgans both have the equivalent of buy ratings on its shares but with price targets of $7.85 and $7.55, respectively. These are both lower than where the company's shares trade today.

Elsewhere, Macquarie and Morgan Stanley have the equivalent of hold ratings with price targets of $7.65 and $6.95, respectively, and Ord Minnett has a lighten rating with a $7.00 price target.

Though, that doesn't necessarily mean that the NIB share price can't keep rising. It just means that brokers are unlikely to be recommending its shares to clients until they are trading at a more attractive level.

In addition, a strong result in August from NIB could have brokers revisiting their models and price targets. Fingers crossed for shareholders that this happens.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »